Table 2 Clinical utility of the 10-year contralateral breast cancer risk prediction model. At the same probability threshold, the net benefit is exemplified in BRCA1/2 mutation carriers (for avoiding unnecessary CPM) and non-carriers (performing necessary CPM)
From: Prediction and clinical utility of a contralateral breast cancer risk model
Probability threshold, pt (%) | Unnecessary CPMs needed to prevent one CBC* | BRCA1/2 mutation carriers | Non-carriers | ||
|---|---|---|---|---|---|
Net benefit versus treat all patients with CPM (per 1000) | Avoided unnecessary CPMs per 1000 patients | Net benefit versus treat none (per 1000) | Performed necessary CPMs per 1000 patients | ||
4 | 24.0 | 0.0 | 0.0 | 3.9 | 93.6 |
5 | 19.0 | 0.0 | 0.0 | 2.1 | 39.9 |
6 | 15.7 | 0.1 | 1.6 | 0.5 | 7.8 |
7 | 13.3 | 1.9 | 25.2 | 0.1 | 1.3 |
8 | 11.5 | 5.5 | 63.3 | 0.0 | 0.0 |
9 | 10.1 | 10.7 | 108.2 | 0.0 | 0.0 |
10 | 9.0 | 17.9 | 161.1 | 0.0 | 0.0 |